SCHEMBL30242017

SCHEMBL30242017

COC(OC)c1ccc(C(N)=O)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 2/20 0.46
KMT2A Q03164 1/20 0.45
NNMT P40261 2/20 0.43
APP P05067 1/20 0.40
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HRH3 Q9Y5N1 2/20 0.35
ADORA3 P0DMS8 1/20 0.35
TSHR P16473 1/20 0.35
MC4R P32245 1/20 0.35
ADRA1A P35348 1/20 0.35
MC3R P41968 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
P4HTM Q9NXG6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29144076 1.00 SIRT6 (0.46) SIRT6KMT2ANNMTAPPPDE4A
SCHEMBL31108226 0.84 KDM4E (0.53) KMT2AMAPK1KDM4EL3MBTL1TSHR
SCHEMBL27080246 0.84 KDM4E (0.53) KMT2AMAPK1KDM4EL3MBTL1TSHR
SCHEMBL9377198 0.83 MAPK1 (0.59) KMT2AMAPK1KDM4EL3MBTL1HRH3
SCHEMBL8953636 0.80 KMT2A (0.49) SIRT6KMT2ANNMTAPPPDE4A
SCHEMBL16465368 0.80 KMT2A (0.53) SIRT6KMT2ANNMTAPPPDE4A
SCHEMBL19304062 0.80 MAPK1 (0.37) SIRT6PDE4AMAPK1KDM4EL3MBTL1
SCHEMBL6469006 0.79 KMT2A (0.47) SIRT6KMT2ANNMTAPPPDE4A
SCHEMBL3923712 0.79 PDE4A (0.43) SIRT6KMT2ANNMTAPPPDE4A
SCHEMBL2655434 0.76 FFAR1 (0.35) SIRT6NNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110582493-B Benzoxazole derivatives as immunomodulators 因赛特公司 2024-03-08 CN disclosed
US-11566026-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566026-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS SIRT6 1563/4885KMT2A 4066/4885NNMT 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.